Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07537075 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Extension of SKY-0515 in Participants With Huntington's Disease

StatusEnrolling by Invitation
PhasePhase 2/3
Started2026-04-10
View on ClinicalTrials.gov ↗

Amendment history

2026-07-23
Study Status v5
Re-verified, no change to tracked fields
2026-07-21
Study Status, Contacts/Locations v4
Trial sites expanded: 4 → 10 locations
2026-05-28
Study Status v3
Re-verified, no change to tracked fields
2026-04-21
Study Status, Contacts/Locations v2
Trial status changed: Not Yet Recruiting → Enrolling by Invitation
Study sitescontacts updated at 1 of 4 sites
2026-04-16
Study Identification, Study Status v1
Study title-11 characters
An Open Label Extension of SKY-0515 in Participants With Huntington's Disease
2026-04-15
Original filing
The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.
Trial Details
NCT Number NCT07537075
Lead Sponsor Skyhawk Therapeutics, Inc.
Conditions Huntington's Disease (HD)
Enrollment 500 participants
Start Date 2026-04-10
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-24